Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublications in collaboration with researchers from Hospital Universitario Marqués de Valdecilla (7)
2024
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432
2021
-
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
JHEP Reports, Vol. 3, Núm. 3
-
Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))
Journal of Hepatology
2020
-
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Liver International, Vol. 40, Núm. 6, pp. 1467-1476
2019
-
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules
Journal of Hepatology, Vol. 70, Núm. 5, pp. 874-884
2018
-
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events
Hepatology, Vol. 67, Núm. 2, pp. 612-622